| Primary |
| Product Used For Unknown Indication |
45.7% |
| Drug Use For Unknown Indication |
44.3% |
| Thrombosis Prophylaxis |
1.8% |
| Haemodialysis |
1.1% |
| Prophylaxis |
1.0% |
| Coronary Artery Bypass |
0.7% |
| Anticoagulant Therapy |
0.7% |
| Catheterisation Cardiac |
0.6% |
| Pain |
0.6% |
| Intravenous Catheter Management |
0.5% |
| Pulmonary Embolism |
0.5% |
| Deep Vein Thrombosis |
0.4% |
| Peritoneal Dialysis |
0.4% |
| Dialysis |
0.3% |
| Atrial Fibrillation |
0.3% |
| Hypertension |
0.3% |
| Myocardial Infarction |
0.2% |
| Cardiac Operation |
0.2% |
| Nausea |
0.2% |
| Central Venous Catheterisation |
0.2% |
|
| Adverse Event |
36.9% |
| Death |
17.2% |
| Vomiting |
16.5% |
| Unresponsive To Stimuli |
5.2% |
| Thrombosis |
2.4% |
| Thrombocytopenia |
2.2% |
| Hypersensitivity |
1.9% |
| Sepsis |
1.9% |
| Respiratory Failure |
1.8% |
| Heparin-induced Thrombocytopenia |
1.7% |
| Wheezing |
1.6% |
| Hypotension |
1.6% |
| Syncope |
1.4% |
| Weight Decreased |
1.3% |
| Ventricular Tachycardia |
1.2% |
| Renal Failure |
1.2% |
| Tachycardia |
1.0% |
| Urinary Tract Infection |
1.0% |
| Pulmonary Embolism |
0.9% |
| Vision Blurred |
0.9% |
|
| Secondary |
| Product Used For Unknown Indication |
67.8% |
| Drug Use For Unknown Indication |
21.0% |
| Thrombosis Prophylaxis |
1.6% |
| Intravenous Catheter Management |
1.4% |
| Haemodialysis |
1.4% |
| Catheterisation Cardiac |
1.1% |
| Coronary Artery Bypass |
1.0% |
| Atrial Fibrillation |
0.5% |
| Prophylaxis |
0.5% |
| Pain |
0.5% |
| Anticoagulant Therapy |
0.4% |
| Deep Vein Thrombosis |
0.4% |
| Thrombectomy |
0.4% |
| Intra-aortic Balloon Placement |
0.3% |
| Aortic Valve Replacement |
0.3% |
| Peritoneal Dialysis |
0.3% |
| Central Venous Catheterisation |
0.3% |
| Pulmonary Embolism |
0.3% |
| Dialysis |
0.3% |
| Acute Myocardial Infarction |
0.2% |
|
| Vomiting |
37.3% |
| Thrombocytopenia |
7.2% |
| Ventricular Tachycardia |
6.8% |
| Unresponsive To Stimuli |
5.7% |
| Weight Decreased |
4.2% |
| Wheezing |
4.1% |
| Respiratory Failure |
3.5% |
| Hypovolaemia |
3.4% |
| Asthenia |
3.3% |
| Tachycardia |
3.1% |
| Thrombosis |
3.1% |
| Sepsis |
2.6% |
| Nausea |
2.5% |
| Hypotension |
2.4% |
| Urinary Tract Infection |
2.3% |
| Abdominal Pain |
2.1% |
| White Blood Cell Count Increased |
1.6% |
| Wound Secretion |
1.6% |
| Chills |
1.6% |
| Hyperhidrosis |
1.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.9% |
| Thrombosis Prophylaxis |
9.8% |
| Osteomyelitis |
8.5% |
| Myasthenia Gravis |
7.2% |
| Hypertension |
6.5% |
| Sepsis |
5.9% |
| Acute Coronary Syndrome |
3.9% |
| Hypercholesterolaemia |
3.9% |
| Nodal Arrhythmia |
3.9% |
| Rheumatoid Arthritis |
3.3% |
| Cardiac Failure |
2.6% |
| Fluid Replacement |
2.6% |
| Gastritis Prophylaxis |
2.6% |
| Induction Of Anaesthesia |
2.6% |
| Insomnia |
2.6% |
| Osteoporosis |
2.6% |
| Prophylaxis |
2.6% |
| Restlessness |
2.6% |
| Maintenance Of Anaesthesia |
2.0% |
| Age-related Macular Degeneration |
1.3% |
|
| Thrombocytopenia |
11.8% |
| Hypotension |
8.8% |
| Pneumocystis Jiroveci Pneumonia |
8.8% |
| Blood Creatinine Increased |
5.9% |
| Electrocardiogram Qt Prolonged |
5.9% |
| Haemoptysis |
5.9% |
| Restlessness |
5.9% |
| Thymectomy |
5.9% |
| Ventricular Fibrillation |
5.9% |
| Ventricular Tachycardia |
5.9% |
| Cholecystitis Acute |
2.9% |
| Death |
2.9% |
| Delirium |
2.9% |
| Dyspnoea |
2.9% |
| Heparin-induced Thrombocytopenia |
2.9% |
| Nephropathy Toxic |
2.9% |
| Product Quality Issue |
2.9% |
| Pulmonary Embolism |
2.9% |
| Pulmonary Hypertension |
2.9% |
| Pulmonary Infarction |
2.9% |
|
